Implications for healthcare leasing and equipment finance
By Willie Foerstner
In a much-anticipated move, on Wednesday the Federal Reserve cut the federal funds rate by 25 basis points (0.25%), bringing the target range down to 4.00%-4.25%.
This is the first rate reduction since December 2024.
Ensure critical devices are ready to go
Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.
Demand outlook
Lower interest rates are likely to encourage health systems, clinics, and physician groups to move forward with deferred capital investments; everything from imaging systems to upgrades in clinical informatics or hospital infrastructure. Entities that were waiting for more favorable financing may now feel the urgency to act while rates are more supportive.
Pricing dynamics
Immediate pressure on lease yields: With the federal funds rate dropped to 4.00 – 4.25% from the prior 4.25 – 4.50% range, funding costs for lenders fall. That gives lessors room to offer more competitive terms, though margins may be squeezed in the near term as competition intensifies.
Fixed vs. floating: Fixed‐rate leases become more attractive in this environment. Floating-rate leases may already price in expectations of further easing, meaning floating borrowers may not yet fully realize benefit until spreads compress.
Credit rating sensitivity: Even with this rate reduction, borrowing costs will still vary significantly by credit. High‐credit healthcare providers are positioned to take full advantage of the cut; others with weaker credit profiles may continue to face high spreads that could undercut much of the nominal rate drop.
Market sentiment
The cut is a clear signal from the Fed that downside risk, especially related to the labor market, is rising. That lends some confidence to providers who are preparing capital budgets for 2026 and beyond. But as always, optimism is tempered: some decision-makers may hold off, betting on the possibility of more rate cuts before firming up large investments.
Role of SOFR in rate prediction
The Secured Overnight Financing Rate (SOFR), now running at approximately 4.39% as of the most recent data, has already been reflecting market expectations that the Fed would begin easing. Because SOFR futures and related forward curves had priced in this move, much of the rate cut is already built into commercial financing models and pricing. What matters now is how steeply the forward curve tilts further lower (or not).
Strategic considerations
Healthcare finance leaders should:
Update pricing models immediately to reflect the new 4.00 – 4.25% benchmark.
Promote fixed-rate lease offerings for clients who prefer certainty.
Remain vigilant about credit spreads — favorable benchmark rates won’t matter much if risk premiums remain high.
Examine equipment financing pipelines: those waiting may find that future cuts are smaller or more uncertain.
Bottom line
The Fed’s 0.25% rate cut, lowering the funds rate to 4.00 – 4.25%, strengthens the case for increased leasing and equipment financing in healthcare. It should boost demand and make pricing more favorable. Nevertheless, because SOFR curves had largely anticipated this cut (SOFR is around 4.39%), much of the benefit may already be embedded in current deals. Ultimately, credit quality will decide who truly captures savings: strong borrowers will benefit, others may still face elevated all-in costs.
About the author: Willie Foerstner is healthcare correspondent at PMAC Capital Reports. Willie leverages his unique blend of clinical insight and capital expertise to report on how innovation is funded, developed, validated, and delivered to patients. From advanced imaging technologies — including photon-counting CT, PET/MR, and myocardial perfusion imaging — to cyclotron-based isotope production, theranostics, and next-generation radiopharmaceutical trials, he offers perspective that bridges financial strategies, regulatory pathways, and patient outcomes. With a passion for advancing therapies that aim to eradicate cancer, he is a committed patient advocate whose mission is to align capital with care, highlight how financial and clinical ecosystems must work together to advance precision medicine, and keep the public informed on what is truly cutting edge.
link
